Telix Pharmaceuticals Limited (TLX)
| Market Cap | 4.05B |
| Revenue (ttm) | 386.76M |
| Net Income (ttm) | 21.26M |
| Shares Out | 341.06M |
| EPS (ttm) | 0.06 |
| PE Ratio | 190.42 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About TLX
Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. Our mission is to be the global leader in radiopharmaceuticals by combining therapeutic and diagnostic modalities for the benefit of patients, an innovative precision medicine concept generally referred to as “theranostics”. We have an extensive pipeline of theranostic radiopharmaceutical product candidates with a focus in urologic oncology (prostate and kidney), neuro-oncolog... [Read more]
News
Telix Announces Launch of Proposed Initial Public Offering in the United States
Telix Pharmaceuticals Limited today announces the launch of its initial public offering in the United States of 17,000,000 American Depositary...
Australian radiopharmaceutical biotech Telix Pharmaceuticals files for a $100 million US IPO
Telix Pharmaceuticals, a commercial-stage Australian biotech developing therapeutic and diagnostic radiopharmaceuticals, filed on Friday with the SEC to raise up to $100 million in an initial public o...
Telix Files Registration Statement for Proposed Initial Public Offering in the United States
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has filed a...
Telix Pharmaceuticals IPO Registration Document (F-1)
Telix Pharmaceuticals has filed to go public with an IPO on the NASDAQ.